Drug Trial Radar · NCT02579226
A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors.
Last checked: Nov 19, 2026Latest source record: May 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Oct 28, 2015
Primary completion
Feb 7, 2020
Study completion Apr 3, 2020
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 19, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase I study is primarily designed to evaluate the safety and tolerability of AZD2811 at increasing doses in patients with advanced solid tumours and for whom no standard of care exists. The study will be conducted in two parts, a dose-escalation phase (Part A) and a dose expansion phase (Part B). During Part A, the dose-escalation phase, patient enrolment will proceed according to a 3+3 design where the maximum tolerated dose (MTD) or the recommended Phase II dose (RP2D) could be identified. The study will also characterize the pharmacokinetic (PK) profile of AZD2811 and will explore the potential biological activity by assessing anti-tumour activity in patients. Part B will further explore PK parameters, safety, tolerability, and preliminary anti-tumour activity of the AZD2811 RP2D as monotherapy (Group 1) in patients with relapsed/refractory SCLC.
Conditions
- Advanced Solid Tumours
Interventions
AZD2811Drug
The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B). All patients in both parts of the study with receive AZD2811.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of dose-limiting toxicites (DLTs)Time frame: Patients will be followed for either 21 or 28 days in Cycle 1 to determine the incidence of Dose Limiting Toxicities (DLTs).
- The incidence of adverse eventsTime frame: Patients will be followed for either 21 or 28 days in Cycle 1 to determine the incidence of adverse events
- The incidence of abnormal laboratory resultsTime frame: Patients will be followed for either 21 or 28 days in Cycle 1 to determine the incidence of abnormal laboratory results.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Research Site
Denver, Colorado
Research Site
Sarasota, Florida
Research Site
Boston, Massachusetts
Research Site
Nashville, Tennessee
Research Site
Houston, Texas
Research Site
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.